Cat. #151655
FLYA-13 Cell Line
Cat. #: 151655
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Disease: Cancer
Model: Packaging
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Mary Collins
Institute: The Institute of Cancer Research London
Tool Details
*FOR RESEARCH USE ONLY
- Name: FLYA-13 Cell Line
- Tool sub type: Continuous
- Parental cell: HT 1080
- Organism: Human
- Disease: Cancer
- Growth properties: Recombinant retroviral production
- Model: Packaging
- Conditional: Yes
- Description: The FLYA-13 Cell Line is a packaging cell line enabling production of high-titer, human complement-resistant recombinant retroviruses, with significantly reduced probability of replication-competent retrovirus generation. HT 1080-based packaging cell line enabling production of recombinant retroviral vectors with Moloney murine leukemia virus cores and amphotropic murine leukemia virus envelopes. The vectors demonstrate high resistance to the inhibitory effects of human serum/complement, in...
- Production details: For details of production of FLYA13 cell line see Cosset et al. 1995. Journal of Virology. 69:7430-36. PMID: 7494248.
- Cellosaurus id: CVCL_8870
Handling
- Format: Frozen
- Growth medium: For recommended growth and recombinant retrovirus production conditions see Cosset F et al, Journal of Virology, 1995, v69 pp7430-7436 & Takeuchi Y et al, Journal of Virology, 1994, v68 pp8001-8007
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Cosset et al. 1995. J Virol. 69(12):7430-6. PMID: 7494248.
- High-titer packaging cells producing recombinant retroviruses resistant to human serum.
- Takeuchi et al. 1994. J Virol. 68(12):8001-7. PMID: 7966590.
- Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.
